C-terminal HSP90 inhibitors to treat pituitary adenomas
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 30, 2018
Issued Date -
N/A
app pub date -
Jan 4, 2014
filing date -
Jan 4, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully